Stay updated with breaking news from Nasdaq vir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Profund Advisors LLC grew its stake in Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 51.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 91,038 shares of the company’s stock after acquiring an additional 31,029 shares during the quarter. Profund […] ....
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report)’s share price was down 2.7% on Tuesday after an insider sold shares in the company. The stock traded as low as $11.42 and last traded at $11.58. Approximately 140,465 shares changed hands during trading, a decline of 87% from the average daily volume of 1,121,850 shares. The […] ....
Vir Biotechnology (NASDAQ:VIR – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.28, Briefing.com reports. Vir Biotechnology had a negative return on equity of 33.82% and a negative net margin of 713.69%. The business had […] ....
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) rose 8.5% on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $11.28 and last traded at $11.18. Approximately 290,356 shares changed hands during trading, a decline of 73% from the average daily volume of 1,084,488 shares. The stock had […] ....
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages […] ....